Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet size trait,,RS:0004633,SD-Fhem1+/+,male,0 days,3,,CMO:0001350,platelet distribution width,,,,9.8,fl,0.4041,0.7,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104917,control condition, 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet size trait,,RS:0004633,SD-Fhem1+/+,female,0 days,3,,CMO:0001350,platelet distribution width,,,,9.5,fl,0.2887,0.5,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104918,control condition, 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet size trait,,RS:0004632,SD-Fhem1+/-,male,0 days,3,,CMO:0001350,platelet distribution width,,,,8.9,fl,0.5774,1.0,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104919,control condition, 2989,"Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429.",platelet size trait,,RS:0004632,SD-Fhem1+/-,female,0 days,3,,CMO:0001350,platelet distribution width,,,,9.8,fl,0.4041,0.7,MMO:0000179,automated blood analysis,,0.0,,,,,control condition,104920,control condition, 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,56 days,20,,CMO:0001350,platelet distribution width,,,,8.5,fl,0.0671,0.3,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) ,107881,DHD/K12/TRb cells (1.5 X 10E6) , 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0001350,platelet distribution width,,,,8.7,fl,0.1581,0.5,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107882,DHD/K12/TRb cells (1.5 X 10E6) ,vehicle control condition (1 ml) 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0001350,platelet distribution width,,,,8.7,fl,0.0632,0.2,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) ,107883,DHD/K12/TRb cells (1.5 X 10E6) ,sanguinarine (5 mg/kg/d) 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0001350,platelet distribution width,,,,8.6,fl,0.0316,0.1,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107884,DHD/K12/TRb cells (1.5 X 10E6) ,vehicle control condition (1 ml) 3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",platelet size trait,,RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0001350,platelet distribution width,,,,8.6,fl,0.0949,0.3,MMO:0000174,automated hematology analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) ,107885,DHD/K12/TRb cells (1.5 X 10E6) ,sanguinarine (5 mg/kg/d)